{"DataElement":{"publicId":"2775200","version":"1","preferredName":"AIDS Malignancy Consortium Patient Inclusion Clinical Trial Eligibility Criteria 059 Type","preferredDefinition":"the type of element of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial of a person who receives medical attention, care, or treatment in a clinical trials cooperative group supported by NCI.","longName":"AMC_PT_I_CTEC_059_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2518231","version":"1","preferredName":"AIDS Malignancy Consortium Patient Inclusion Clinical Trial Eligibility Criteria","preferredDefinition":"information relating to the elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial of a person who receives medical attention, care, or treatment in a clinical trials cooperative group supported by NCI.","longName":"AMC_PT_INCL_CTEC","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2518228","version":"1","preferredName":"AIDS Malignancy Consortium Patient","preferredDefinition":"Established in 1995 to carry out Phase I and II studies of innovative therapies for AIDS malignancies.:A person who requires medical care.","longName":"C19707:C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AIDS Malignancy Consortium","conceptCode":"C19707","definition":"Established in 1995 to carry out Phase I and II studies of innovative therapies for AIDS malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC96D39-08C6-6793-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2518229","version":"1","preferredName":"Inclusion Clinical Trial Eligibility Criteria","preferredDefinition":"The addition of somebody or something to, or the presence of somebody or something in, a group or mixture, particularly, a passive, usually temporary, product of cell activity within the cytoplasm or nucleus.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C25532:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inclusion Criteria","conceptCode":"C25532","definition":"Medical and/or social characteristics which are necessary for a subject to be allowed to participate in a clinical study, as outlined in the study protocol. Meeting inclusion criteria is not a sufficient condition for entry or recruitment of a subject into the study. Characteristics limiting the eligibility of a subject for the clinical study must be considered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC96D39-08D4-6793-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC977E8-B49D-6863-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2775201","version":"1","preferredName":"059 Inclusion Clinical Trial Eligibility Criteria Type","preferredDefinition":"the type of clinical trial eligibility inclusion criteria for an AIDS Malignancy Consortium 059 protocol.","longName":"059_INCL_CTEC_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"255","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Does the participant have biopsy-proven KS involving the skin, with or without lymph node, oral cavity, gastrointestinal (GI) tract and/or lung involvement","valueDescription":"Does the participant have biopsy-proven KS involving the skin, with or without lymph node, oral cavity, gastrointestinal (GI) tract and/or lung involvement","ValueMeaning":{"publicId":"2775207","version":"1","preferredName":"Does the participant have biopsy-proven KS involving the skin, with or without lymph node, oral cavity, gastrointestinal (GI) tract and/or lung involvement","longName":"2775207","preferredDefinition":"Does the participant have biopsy-proven KS involving the skin, with or without lymph node, oral cavity, gastrointestinal (GI) tract and/or lung involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54E6703C-5013-31AA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54E674F0-AF1A-2D82-E044-0003BA3F9857","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"ONEDATA","dateModified":"2008-08-20","deletedIndicator":"No"},{"value":"Does the participant have at least five measurable, previously non-radiated, cutaneous lesions present which can be used as indicator lesions","valueDescription":"Does the participant have at least five measurable, previously non-radiated, cutaneous lesions present which can be used as indicator lesions","ValueMeaning":{"publicId":"2775206","version":"1","preferredName":"Does the participant have at least five measurable, previously non-radiated, cutaneous lesions present which can be used as indicator lesions","longName":"2775206","preferredDefinition":"Does the participant have at least five measurable, previously non-radiated, cutaneous lesions present which can be used as indicator lesions","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54E67261-1CA8-2DA0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54E674F0-AF2C-2D82-E044-0003BA3F9857","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"ONEDATA","dateModified":"2008-08-20","deletedIndicator":"No"},{"value":"Does the participant have four non-indicator cutaneous lesions present measuring >=4 x 4mm that are accessible for 3 mm punch biopsy","valueDescription":"Does the participant have four non-indicator cutaneous lesions present measuring >=4 x 4mm that are accessible for 3 mm punch biopsy","ValueMeaning":{"publicId":"2775205","version":"1","preferredName":"Does the participant have four non-indicator cutaneous lesions present measuring >=4 x 4mm that are accessible for 3 mm punch biopsy","longName":"2775205","preferredDefinition":"Does the participant have four non-indicator cutaneous lesions present measuring >=4 x 4mm that are accessible for 3 mm punch biopsy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54E6703C-5003-31AA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54E674F0-AF3E-2D82-E044-0003BA3F9857","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"ONEDATA","dateModified":"2008-08-20","deletedIndicator":"No"},{"value":"Does the participant have serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive ELISA, positive Western Blot, or other federally approved licensed HIV test, or a detectable blood level of HIV RNA","valueDescription":"Does the participant have serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive ELISA, positive Western Blot, or other federally approved licensed HIV test, or a detectable blood level of HIV RNA","ValueMeaning":{"publicId":"2649457","version":"1","preferredName":"Does the participant have serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive ELISA, positive Western Blot, or other federally approved licensed HIV test, or a detectable blood level of HIV RNA","longName":"2649457","preferredDefinition":"Does the participant have serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive ELISA, positive Western Blot, or other federally approved licensed HIV test, or a detectable blood level of HIV RNA","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32653064-8231-372A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54E674F0-AF4A-2D82-E044-0003BA3F9857","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"ONEDATA","dateModified":"2008-08-20","deletedIndicator":"No"},{"value":"Karnofsky Performance Status (must be > 60%)","valueDescription":"Karnofsky Performance Status (must be > 60%)","ValueMeaning":{"publicId":"2580739","version":"1","preferredName":"Karnofsky Performance Status (must be > 60%)","longName":"2580739","preferredDefinition":"Karnofsky Performance Status (must be > 60%)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0870-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SHIDED","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54E674F0-AF55-2D82-E044-0003BA3F9857","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"ONEDATA","dateModified":"2008-08-20","deletedIndicator":"No"},{"value":"Does the participant have the following laboratory parameters within 21 days prior to enrollment: hemoglobin > 8.0 gm/dL; absolute neutrophil count >= 1000 cells/mm^3; platelet count >= 75,000/mm^3","valueDescription":"Does the participant have the following laboratory parameters within 21 days prior to study entry: Hemoglobin >= 8.0 gm/dL; Absolute neutrophil count >= 1000 cells/mm3; Platelet count >= 75,000/mm3","ValueMeaning":{"publicId":"2649462","version":"1","preferredName":"Does the participant have the following laboratory parameters within 21 days prior to study entry: Hemoglobin >= 8.0 gm/dL; Absolute neutrophil count >= 1000 cells/mm3; Platelet count >= 75,000/mm3","longName":"2649462","preferredDefinition":"Does the participant have the following laboratory parameters within 21 days prior to study entry: Hemoglobin >= 8.0 gm/dL; Absolute neutrophil count >= 1000 cells/mm3; Platelet count >= 75,000/mm3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32651845-D98B-3B9F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54E674F0-AF66-2D82-E044-0003BA3F9857","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"ONEDATA","dateModified":"2008-08-20","deletedIndicator":"No"},{"value":"Does the participant have the following laboratory parameters within 21 days prior to enrollment: creatinine <=2.0 mg/dL; AST (SGOT) and ALT (SGPT) <= 2.5 x ULN; INR and aPTT <=  ULN;  does the participant have an INR and aPTT <= ULN; < 2+ proteinuria","valueDescription":"Does the participant have the following laboratory parameters within 21 days prior to enrollment: creatinine <=2.0 mg/dL; AST (SGOT) and ALT (SGPT) <= 2.5 x ULN; INR and aPTT <=  ULN;  does the participant have an INR and aPTT <= ULN; < 2+ proteinuria","ValueMeaning":{"publicId":"2775212","version":"1","preferredName":"Does the participant have the following laboratory parameters within 21 days prior to enrollment: creatinine <=2.0 mg/dL; AST (SGOT) and ALT (SGPT) <= 2.5 x ULN; INR and aPTT <=  ULN;  does the participant have an INR and aPTT <= ULN; < 2+ proteinuria","longName":"2775212","preferredDefinition":"Does the participant have the following laboratory parameters within 21 days prior to enrollment: creatinine <=2.0 mg/dL; AST (SGOT) and ALT (SGPT) <= 2.5 x ULN; INR and aPTT <=  ULN;  does the participant have an INR and aPTT <= ULN; < 2+ proteinuria","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54E58361-C536-2D56-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54E674F0-AF77-2D82-E044-0003BA3F9857","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"ONEDATA","dateModified":"2008-08-20","deletedIndicator":"No"},{"value":"Does the participant have a total bilirubin <=1.5 times upper limit of normal (ULN) Is the elevated bilirubin felt to be secondary to Indinavir or Atazanavir therapy Is total bilirubin <= 3.5 mg/dl and is direct bilirubin normal","valueDescription":"Does the participant have a total bilirubin <=1.5 times upper limit of normal (ULN) Is the elevated bilirubin felt to be secondary to Indinavir or Atazanavir therapy Is total bilirubin <= 3.5 mg/dl and is direct bilirubin normal","ValueMeaning":{"publicId":"2775211","version":"1","preferredName":"Does the participant have a total bilirubin <=1.5 times upper limit of normal (ULN) Is the elevated bilirubin felt to be secondary to Indinavir or Atazanavir therapy Is total bilirubin <= 3.5 mg/dl and is direct bilirubin normal","longName":"2775211","preferredDefinition":"Does the participant have a total bilirubin <=1.5 times upper limit of normal (ULN) Is the elevated bilirubin felt to be secondary to Indinavir or Atazanavir therapy Is total bilirubin <= 3.5 mg/dl and is direct bilirubin normal","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54E66BA7-C41D-2DB2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54E674F0-AF89-2D82-E044-0003BA3F9857","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"ONEDATA","dateModified":"2008-08-20","deletedIndicator":"No"},{"value":"Is the participant's life expectancy 3 months or more","valueDescription":"Is the participant's life expectancy 3 months or more","ValueMeaning":{"publicId":"2649470","version":"1","preferredName":"Is the participant's life expectancy 3 months or more","longName":"2649470","preferredDefinition":"Is the participant's life expectancy 3 months or more","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32651F9F-1D26-3BDA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54E674F0-AF95-2D82-E044-0003BA3F9857","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"ONEDATA","dateModified":"2008-08-20","deletedIndicator":"No"},{"value":"Does the participant have the ability and willingness to give written informed consent","valueDescription":"Does the participant have the ability and willingness to give written informed consent","ValueMeaning":{"publicId":"2775209","version":"1","preferredName":"Does the participant have the ability and willingness to give written informed consent","longName":"2775209","preferredDefinition":"Does the participant have the ability and willingness to give written informed consent","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54E65CE3-2089-2D54-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54E674F0-AFA6-2D82-E044-0003BA3F9857","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"ONEDATA","dateModified":"2008-08-20","deletedIndicator":"No"},{"value":"Date informed consent obtained","valueDescription":"Date informed consent obtained","ValueMeaning":{"publicId":"2580745","version":"1","preferredName":"Date informed consent obtained","longName":"2580745","preferredDefinition":"Date informed consent obtained","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0876-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SHIDED","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54E61CEA-62FC-2DAC-E044-0003BA3F9857","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"ONEDATA","dateModified":"2008-08-20","deletedIndicator":"No"},{"value":"If the participant is female, and of child-bearing potential, has she had a negative pregnancy test prior to study entry","valueDescription":"If the participant is female, and of child-bearing potential, has she had a negative pregnancy test prior to study entry","ValueMeaning":{"publicId":"2775215","version":"1","preferredName":"If the participant is female, and of child-bearing potential, has she had a negative pregnancy test prior to study entry","longName":"2775215","preferredDefinition":"If the participant is female, and of child-bearing potential, has she had a negative pregnancy test prior to study entry","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54E67261-1CB8-2DA0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54E61CEA-630D-2DAC-E044-0003BA3F9857","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"ONEDATA","dateModified":"2008-08-20","deletedIndicator":"No"},{"value":"Does the participant agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug","valueDescription":"Does the participant agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug","ValueMeaning":{"publicId":"2775214","version":"1","preferredName":"Does the participant agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug","longName":"2775214","preferredDefinition":"Does the participant agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54E65CE3-2099-2D54-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54E61CEA-631F-2DAC-E044-0003BA3F9857","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"ONEDATA","dateModified":"2008-08-20","deletedIndicator":"No"},{"value":"Is the participant, in the opinion of the Investigator, capable of complying with this protocol","valueDescription":"Is the participant, in the opinion of the Investigator, capable of complying with this protocol","ValueMeaning":{"publicId":"2649473","version":"1","preferredName":"Is the participant, in the opinion of the Investigator, capable of complying with this protocol","longName":"2649473","preferredDefinition":"Is the participant, in the opinion of the Investigator, capable of complying with this protocol","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32651AA4-03DC-3BA1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54E61CEA-632B-2DAC-E044-0003BA3F9857","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"ONEDATA","dateModified":"2008-08-20","deletedIndicator":"No"},{"value":"Is the participant on antiretroviral therapy","valueDescription":"Is the participant on antiretroviral therapy","ValueMeaning":{"publicId":"2775213","version":"1","preferredName":"Is the participant on antiretroviral therapy","longName":"2775213","preferredDefinition":"Is the participant on antiretroviral therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54E58361-C546-2D56-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54E61CEA-633C-2DAC-E044-0003BA3F9857","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"ONEDATA","dateModified":"2008-08-20","deletedIndicator":"No"},{"value":"Has the participant been on stable antiretroviral therapy for at least 12 weeks","valueDescription":"Has the participant been on stable antiretroviral therapy for at least 12 weeks","ValueMeaning":{"publicId":"2775216","version":"1","preferredName":"Has the participant been on stable antiretroviral therapy for at least 12 weeks","longName":"2775216","preferredDefinition":"Has the participant been on stable antiretroviral therapy for at least 12 weeks","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54E65DC1-FED8-3438-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54E59AAA-07B2-2D52-E044-0003BA3F9857","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"ONEDATA","dateModified":"2008-08-20","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2177853","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"Type","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C16D625D-02B6-1907-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-07-09","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-07-09","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"54E65CE3-2074-2D54-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"SHIDED","dateModified":"2011-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Inclusion Criteria","type":"Preferred Question Text","description":"Inclusion Criteria","url":null,"context":"CTEP"}],"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"54E64E45-4FF2-326F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"CAMPBELB","dateModified":"2011-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}